Hims vs. Novo Nordisk: Why the Pharma Giant Might Avoid a Legal Fight
Hims is selling a $49 copycat of Novo Nordisk's $149 weight-loss pill, but legal experts say Novo may avoid court battles due to risks of setting dangerous precedents.
NOTRELOAD AI
Apple Bucks Big Tech's AI Spending Frenzy While Cloud Backlogs Hit $1.1 Trillion
While Amazon, Google, Meta, and Microsoft pour record billions into AI infrastructure, Apple takes a different approach—and Big Tech cloud backlogs reach unprecedented levels.
Under Armour Beats Expectations, Raises 2026 Outlook Despite Tariff Headwinds
Under Armour (UA) stock jumps 11% as Q3 results exceed forecasts. Company raises annual profit outlook while navigating tariffs and business transformation with premium product focus.
uniQure's Fabry Disease Gene Therapy Shows Promising Results in Early Trial
AMT-191 gene therapy demonstrates sustained enzyme activity increases in Fabry disease patients, with 6 of 11 stopping traditional infusion therapy.
Deutsche Bank Upgrades ViaSat to Buy with $48 Price Target
ViaSat upgraded to Buy by Deutsche Bank as upcoming satellites and a Defense spinoff boost growth prospects.
Refresco Acquires SunOpta for $6.50 Per Share in Strategic Beverage Deal
Beverage giant Refresco to acquire SunOpta for $6.50/share in cash, expanding its plant-based beverage portfolio and North American presence. Deal expected Q2 2026.